Perifosine 201: A Phase 1/2 trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer

Drug: Perifosine

All patients should continue therapy on their current regimen until disease progression.

Experimental: 2

Perifosine 206: A Randomized Phase II Trial of Three Doses of Perifosine in Combination With Trastuzumab

Drug: Perifosine

All patients should continue therapy on their current regimen until disease progression

Experimental: 3

Perifosine 207: A Phase IIA Trial of Two Schedules of Perifosine

Drug: Perifosine

All patients should continue therapy on their current regimen until disease progression

Experimental: 4

Perifosine 208: A Phase II Trial of Two Schedules of Perifosine in Combination with Endocrine Therapy for Patients with Estrogen Receptor or Progesterone Receptor Positive Metastatic Breast Cancer

Drug: Perifosine

All patients should continue therapy on their current regimen until disease progression

Experimental: 5

Perifosine 209: A Phase II Trial of Perifosine in Patients with Sarcomas

Drug: Perifosine

All patients should continue therapy on their current regimen until disease progression

Detailed Description:

Perifosine is an oral anticancer agent with limited toxicity and a novel mechanism of action that is distinctly different from cytotoxic chemotherapies. It has been shown to inhibit and otherwise modify signaling through a number of pathways including Akt, p21, and JNK. Perifosine has been tested in Phase I and Phase II settings in a variety of dosing schedules including daily, weekly, and daily following a loading dose. In general, it has been well tolerated with dose-related nausea, vomiting, diarrhea, and fatigue being the most commonly observed toxicities.

Perifosine has induced partial responses or stable disease in solid tumors including but not limited to renal cell, sarcoma, and hepatocellular carcinoma. Perifosine is currently being studied in multiple diseases as a single agent as well as in combination with other cancer therapies. As studies are closed there are patients that have achieved a partial response or stable disease.

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Patients must be currently receiving treatment with perifosine on a previously approved protocol.

Patients must have had at least one evaluation following the initiation of treatment and have stable disease, partial response or complete response.

Patient is willing to sign a new consent

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.